ReviewJournal of medicinal chemistry2022
Sialidase Inhibitors with Different Mechanisms.
Review in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- Systematic identification of bacterial neuraminidase inhibitors fromJournal of enzyme inhibition and medicinal chemistry · 2026Article
- N6-methyladenosine modification of NEU1 mediated by METTL3 exacerbates angiotensin II-induced atrial fibrillation.Cell adhesion & migration · 2026Article
- Novel Phloroglucinol Derivatives as Neuraminidase Inhibitors Identified From Humulus lupulus L. Extract by At-Line Nanofractionation Platform.Electrophoresis · 2026Article
- Synthesis and Glycosidase Inhibition Studies of Novel Exoglycals Targeting GH3 Family Enzymes: Insights from Comparative Analysis with Macrolide Antibiotics.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Backbone N-Methylation Improves PPCA-Binding of a Stylissatin A Analogue via Conformational Modulation.Chemistry, an Asian journal · 2026Article
- Fluorinated carbohydrate-based vaccines.Chemical science · 2026Review
- Dynamic proteomics of Nasonia vitripennis pupal development reveals testis-specific regulation of new proteins (orphans) likely related to exo-α-sialidases.BMC genomics · 2026Article
- Development of a C5-Azidoacetamide-Modified 4-Amino-2,3-Difluorosialic Acid Activity-Based Probe for Labeling of Influenza A Neuraminidases.Chembiochem : a European journal of chemical biology · 2026Article
- Effect of sialidase inhibitors on a plaque community biofilm model.Access microbiology · 2026Article
- Decoding sialidase: physiological roles, pathological pathways, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Clinical analysis of association between vaginal microbiota indicators and HPV infection.Frontiers in global women's health · 2026Article
- Discovery of Influenza Neuraminidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation of Novel Chemotypes.Molecules (Basel, Switzerland) · 2025Article
- Selective labeling and visualization of viral and bacterial neuraminidases usingRSC chemical biology · 2025Article
- Sialidases as Potential Therapeutic Targets for Treatment of a Number of Human Diseases.International journal of molecular sciences · 2025Review
- Improved C5-Amide Bioisosteres for Human Neuraminidase 1 Inhibitors Based on 2-Deoxy-2,3-Didehydro-N-Acetyl Neuraminic Acid.ChemMedChem · 2025Article
- Catch, Cut, or Block? Versatile 4-N-Derivatized Sialyl Glycosides for Influenza Virus Neuraminidase Detection and Purification.Angewandte Chemie (International ed. in English) · 2025Article
- Neuraminidase as a novel therapeutic management strategy for Alzheimer's disease: evidenced through molecular docking, molecular dynamic simulation and gene expression analysis.Frontiers in chemistry · 2025Article
- A comparative study of the substrate preference of the sialidases, CpNanI, HpNanH, and BbSia2 towards 2-Aminobenzamide-labeled 3'-Sialyllactose, 6'-Sialyllactose, and Sialyllacto-N-tetraose-b.Biochemistry and biophysics reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in biological pathways. Inhibition of sialidases with inhibitors is an important approach for understanding sialidase function and the underlying mechanisms and could serve as a therapeutic approach as well. Transition-state analogues, such as anti-influenza drugs oseltamivir and zanamivir, are major sialidase inhibitors. In addition, difluoro-sialic acids were developed as mechanism-based sialidase inhibitors. Further, fluorinated quinone methide-based suicide substrates were reported. Sialidase product analogue inhibitors were also explored. Finally, natural products have shown competitive inhibiton against viral, bacterial, and human sialidases. This Perspective describes sialidase inhibitors with different mechanisms and their activities and future potential, which include transition-state analogue inhibitors, mechanism-based inhibitors, suicide substrate inhibitors, product analogue inhibitors, and natural product inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.